Profile: NovaBay Pharmaceuticals Inc (NBY.A)
19 Aug 2014
NovaBay Pharmaceuticals, Inc., incorporated on January 19, 2000, is a clinical-stage biotechnology company focused on addressing the unmet therapeutic needs of the global anti-infective market. The Company’s Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a spectrum of activity against bacteria, viruses and fungi. The Company is focused in three therapeutic markets, which includes Dermatology, Ophthalmology and Urology. The Company is also developing another class of molecule, NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care.
The Company is developing a gel formulation of NVC-422 for treating the contagious skin infection, impetigo. The Company is developing an eye drop formulation of NVC-422 for treating viral conjunctivitis. The Company’s irrigation solution containing NVC-422 is in Phase 2 clinical studies, with the goal of reducing the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections.
The Company competes with Pfizer, Inc., Johnson & Johnson, Abbott Grp. Plc., GlaxoSmithKline Plc, Sanofi-Aventis SA, Novartis AG, Smith & Nephew Plc, C.R. Bard, Puricore and Oculus Innovative Sciences.
NovaBay Pharmaceuticals Inc
Suite 550, 5980 Horton Street
EMERYVILLE CA 94608